Focus on HIV Care

Back to articles

Antiretroviral Successes, Failures Highlighted at ICAAC

KEY POINT

Use of antiretroviral agents for treating patients with HIV infection is being altered as a result of findings from several studies presented last month at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago.

SOURCES

Gallant JE et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. Abstract H-1722a. 

Van Leth F et al. Nevirapine and efavirenz have a comparable viral decay rate which is not associated with virologic failure. Abstract H-848. 

Gathe JC et al. Preliminary pilot data on the safety and efficacy of Kaletra (LPV/r) dosed alone for the treatment of HIV in ARV-naive patients. Abstract H-845.

Gil P et al. Efficacy and safety of protease inhibitor (PI) switching to nevirapine (NVP) in HIV patients with undetectable viral load: results after 3 years. Abstract H-846.